Pharmacokinetic Study of High Dose Etoposide Infusion in Patients with Small Cell Lung Cancer (original) (raw)
The plasma pharmacokinetics of etoposide administered at a dose of 600 mg/m*/day over 3 consecutive days to 19 patients are described. High performance liquid chromatography with ultraviolet detection was used to determine the etoposide levels. The plasma concentration time curve showed a biphasic decay. When given as a 6-h infusion of 600 mg/m2 on each of 3 consecutive days, the peak plasma levels (PPL) were 45.6 k SD 10.5 pg/ml, and the area under the curve (AUC) values were 1379.6kSD 332.4 pg/rnl/h. In 2 patients a second cycle 28 days later as a 72-h infusion at a total dose of 1800 mg/m2 was given, and in these cases the mean PPL was 30 p g h l compared to 63 &ml for the 6h infusion in the same patients, and the mean AUC was 1239 pg/ml/h compared to 1952.5 pg/ml/h. There was no correlation with age, sex, the duration of or the severity of the neutropenia. It is concluded that high dose etoposide has higher PPL and improved concentration x time values when given as 3 consecutive daily infusions 18 h apart than as a continuous 72 h infusion.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.